Intravitreal Avastin: The Low Cost Alternative to Lucentis?
Author:
- Philip J. RosenfeldPRPhilip J. Rosenfeld
- 1 July 2006
- journal article
- editorial
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 142 (1) , 141-143
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- INTRAVITREAL BEVACIZUMAB TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATIONRetina, 2006
- ELECTROPHYSIOLOGIC FINDINGS AFTER INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENTRetina, 2006
- INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT OF PROLIFERATIVE DIABETIC RETINOPATHY COMPLICATED BY VITREOUS HEMORRHAGERetina, 2006
- RAPID IMPROVEMENT OF RUBEOSIS IRIDIS FROM A SINGLE BEVACIZUMAB (AVASTIN) INJECTIONRetina, 2006
- INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR REFRACTORY PSEUDOPHAKIC CYSTOID MACULAR EDEMARetina, 2006
- INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT OF MACULAR EDEMA IN CENTRAL RETINAL VEIN OCCLUSIONRetina, 2006
- Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular DegenerationOphthalmology, 2006
- Maximum Tolerated Dose of a Humanized Anti–Vascular Endothelial Growth Factor Antibody Fragment for Treating Neovascular Age-Related Macular DegenerationOphthalmology, 2005
- Pegaptanib for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2004
- Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degenerationOphthalmology, 2003